RegulatoryJul 7, 2026, 07:59 AM
BIO-key Stock to Recommence Trading on Nasdaq
AI Summary
BIO-key International announced its common stock will recommence trading on the Nasdaq Capital Market on Wednesday, July 8, 2026. This follows a Nasdaq Hearings Panel's determination that the company has regained compliance with continued listing standards, including minimum bid price and SEC filing requirements. The company will be subject to a Discretionary Panel Monitor for one year. CEO Michael DePasquale expressed gratitude to Nasdaq and highlighted the company's growing recurring revenue, solid financial position, and streamlined cost structure, anticipating significantly improved results this year.
Key Highlights
- BIO-key common stock will recommence trading on Nasdaq Capital Market on July 8, 2026.
- Nasdaq Hearings Panel determined the company regained compliance with listing standards.
- Compliance includes minimum bid price and SEC filing requirements.
- BIO-key will be subject to a Discretionary Panel Monitor until July 6, 2027.
- CEO highlighted growing recurring revenue, strong financial position, and streamlined cost structure.
- Management anticipates significantly improved results for the current year.
Price Impact
More from BKYI